| Literature DB >> 25404919 |
Moon-Soo Lee1, Purnima Anumagalla2, Prasanth Talluri2, Mani N Pavuluri2.
Abstract
OBJECTIVES: Identifying early markers of brain function among those at high risk (HR) for pediatric bipolar disorder (PBD) could serve as a screening measure when children and adolescents present with subsyndromal clinical symptoms prior to the conversion to bipolar disorder. Studies on the offspring of patients with bipolar disorder who are genetically at HR have each been limited in establishing a biomarker, while an analytic review in summarizing the findings offers an improvised opportunity toward that goal.Entities:
Keywords: GingerALE; amygdala; dorsolateral prefrontal cortex; high risk; meta-analysis; pediatric bipolar disorder
Year: 2014 PMID: 25404919 PMCID: PMC4217331 DOI: 10.3389/fpsyt.2014.00141
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Figure 1Flow chart of the literature search for included studies.
Primary fMRI studies of participants with pediatric bipolar disorder (PBD), those at high risk (HR) for PBD, and typically developing (TD): children included in meta-analysis.
| Primary study | Sample size | Age (mean ± standard deviation, years) | Medication status | Task |
|---|---|---|---|---|
| Cerullo et al. ( | PBD (11, female = 7), TD (13, female = 6) | Age range: 11–18, PBD: 14.2 ± 1.5, TD: 14.5 ± 1.9 | All bipolar participants had been off atypical anti-psychotics for at least 72 h and had undetectable levels of mood stabilizers. | Continuous performance task with a response inhibition component |
| Chang et al. ( | PBD (12, all male), TD (10, all male) | Age range: 9–18, PBD: 14.7 ± 3.0, TD: 14.4 ± 3.2 | All PBD participants except one were taking medication at the time of the fMRI. | Two-back visuospatial working memory task and an affective task showing emotionally valenced pictures |
| Deveney et al. | PBD (19, female = 12), HR (13, female = 7), TD (21, female = 8) | PBD: 14.76 ± 2.9, HR: 13.46 ± 1.8, TD: 13.78 ± 2.0 | 10 of 19 PBD participants were medicated. | Stop signal task |
| Deveney et al. ( | PBD (32, female = 17), TD (21, female = 8) | Age range: 8–18, PBD: 14.5 ± 2.5, TD: 13.8 ± 2.0 | 17 of 32 PBD youths were medicated. | Stop signal task |
| Dickstein et al. ( | PBD (16, female = 7), TD (16, female = 7) | Age range: 7–18, PBD: 14.1 ± 2.5, TD: 13.9 ± 2.4 | 13 of 16 PBD youths were medicated. | Probabilistic reversal task |
| Dickstein et al. ( | PBD (23, female = 14), TD (22, female = 12) | PBD: 14.2 ± 3.1, TD: 14.7 ± 2.3 | 18 of 23 PBD youths were medicated. | Encoding task and subsequent memory task |
| Diler et al. ( | PBD (10, female = 8), TD (10, female = 8) | Age range: 12–17, PBD: 15.6 ± 0.9, TD: 15.6 ± 1.2 | 7 of 10 youths were medicated. | Emotional face gender-labeling task |
| Diler et al. ( | PBD (10, female = 8), TD (10, female = 8) | Age range: 12–17, PBD: 15.6 ± 0.9, TD: 15.6 ± 1.2 | All PBD youths were medicated. | Go/no go block design cognitive control task |
| Garrett et al. ( | PBD (20, female = 6), TD (21, female = 8) | Age range: 9–17, PBD: 15.63 ± 2.10, TD: 15.35 ± 2.68 | Exact total percentage of medicated participants was not shown. | Emotional (happy, sad, and neutral) facial expression |
| Kim et al. | PBD (28, female = 16), HR (13, female = 7), TD (21, female = 8) | Age range: 8–17, PBD: 14.37 ± 2.63, HR: 13.90 ± 2.02, TD: 13.73 ± 1.96 | 18 of 28 PBD youths were medicated. | The change task |
| Kim et al. ( | PBD (18, female = 8), TD (15, female = 10) | Age range: 9–18, PBD: 14.29 ± 2.54, TD: 14.98 ± 2.03 | 15 of 18 PBD youths were medicated. | Emotional face gender-labeling task |
| Ladouceur et al. | HR (16, female = 7), TD (15, female = 11) | Age range: 8–17, HR: 14.2 ± 2.3, TD: 13.8 ± 2.7 | All participants were unmedicated. | Emotional face N-Back task |
| Leibenluft et al. ( | PBD (26, female = 14), TD (17, female = 8) | PBD: 13.6 ± 2.6, TD: 14.6 ± 1.8 | 13 of 26 PBD youths were medicated. | Stop signal task |
| Mourao-Miranda et al. | HR (16, female = 9), TD (16, female = 9) | Age range: 12–17, HR: 14.8 ± 1.8, TD: 15.3 ± 1.2 | All participants were unmedicated. | Emotional face gender-labeling task |
| Nelson et al. ( | PBD (25, female = 13), TD (17, female = 8) | Age range: 8–17, PBD: 13.4 ± 2.5, TD: 14.6 ± 1.8 | 13 of 25 PBD youths were medicated. | The change task |
| Olsavsky et al. | PBD (32, female = 15), HR (13, female = 6), TD (56, female = 30) | Age range: 8–18, PBD: 14.7 ± 2.7, HR: 14.0 ± 2.4, TD: 14.0 ± 2.6 | 24 of 32 PBD and 1 of HR youths were medicated. | Emotional face presentation |
| Passarotti et al. ( | PBD (15, female = 8), TD (15, female = 8) | Age range: 10–18, PBD: 13.20 ± 2.65, TD: 14.13 ± 3.16 | 8 of 15 PBD youths had been medicated in the past. Patients were drug-free for at least 7 days before testing. | Stop signal task |
| Passarotti et al. ( | PBD (23, female = 13), TD (19, female = 10) | Age range: 10–18, PBD: 13.55 ± 2.48, TD: 13.53 ± 3.16 | All participants were medication free or had a washout period of at least 4–7 days before scanning. | Emotional face N-Back task |
| Passarotti et al. ( | PBD (17, female = 11), TD (14, female = 7) | Age range: 10–18, PBD: 14.27 ± 1.98, TD: 14.14 ± 2.42 | All participants were medication free or had a washout period. | Emotional valence Stroop task |
| Passarotti et al. ( | PBD (17, female = 12), TD (13, female = 7) | Age range: 10–18, PBD: 14.29 ± 2.05, TD: 14.38 ± 3.57 | All patients were medication free for at least 7 days prior to scanning. | Emotional face N-Back task |
| Pavuluri et al. ( | PBD (10, female = 4), TD (10, female = 5) | Age range: 12–18, PBD: 14.9 ± 1.85, TD: 14.3 ± 2.36 | All participants were unmedicated. | Emotional face presentation |
| Pavuluri et al. ( | PBD (10, female = 5), TD (10, female = 5) | Age range: 12–18, PBD: 15.2 ± 2.0, TD: 14.3 ± 2.1 | All participants were unmedicated. | Incidental and directed emotion-processing task |
| Pavuluri et al. ( | PBD (13, female = 3), TD (13, female = 9) | Age range: 10–18, PBD: 14.4 ± 2.2, TD: 14.4 ± 2.8 | All patients were medication free for at least 4–7 days prior to scanning. | Response inhibition task |
| Pavuluri et al. ( | PBD (17, female = 11), TD (14, female = 7) | Age range: 12–18, PBD: 14.3 ± 1.1, TD: 14.1 ± 2.4 | All participants were unmedicated. | Pediatric affective color matching task |
| Rich et al. ( | PBD (22, female = 12), TD (21, female = 10) | Ager range: 9–17, PBD: 14.2 ± 3.1, TD: 14.5 ± 2.5 | 18 of 22 PBD youths were medicated. | Emotional face presentation |
| Singh et al. ( | PBD (24, female = 11), TD (24, female = 15) | Age range: 13–18, PBD: 15.7 ± 1.7, TD: 15.0 ± 1.4 | 20 of 24 PBD participants had a history of medication exposure. | Monetary incentive delay task, affective priming task |
| Singh et al. ( | PBD (26, female = 7), TD (22, female = 9) | Age range: 9–18, PBD: 15.4 ± 2.37, TD: 14.3 ± 2.33 | History of medication exposure: valproic acid (13), lithium (8), antidepressants (16), atypical anti-psychotics (6), psychostimulants (14), or more than one medication (16). | Go/no go block design cognitive control task |
| Thermenos et al. | HR (10, female = 5), TD (10, female = 5) | Age range: 13–24, HR: 18.4 ± 4.2, TD: 17.1 ± 1.4 | All participants were unmedicated. | 2-back working memory task and 0-back control task |
| Weathers et al. ( | PBD (16, female = 8), TD (21, female = 9) | PBD: 14.65 ± 2.19, TD: 13.79 ± 1.97 | 9 of 16 PBD youths were medicated. | Stop signal task |
.
Some studies were missing age range information and showed only the mean age. Accordingly, that information could not be included within the table. Specific medications were heterogeneous when reported and at times went unreported. Hence, we were only able to comment on participants’ medicated/unmedicated status. Similarly, the mood and affect of participants were also largely unreported and, therefore, could not be included in the table.
Activation likelihood estimation (ALE) meta-analysis findings for fMRI studies comparing pediatric bipolar disorder (PBD) patients, participants with a high risk (HR) for PBD, and typically developing (TD) children.
| Pairwise analysis | Side | Brain region | BA | Talairach | Cluster size (mm3) | Extreme value | ||
|---|---|---|---|---|---|---|---|---|
| HR youths > TD youths (11 experiments) | L | Cerebellum, culmen | −8 | −50 | −26 | 1472 | 0.022 | |
| −14 | −36 | −22 | 0.014 | |||||
| −2 | −54 | −10 | 952 | 0.021 | ||||
| R | Dorsolateral prefrontal cortex | 9 | 46 | 8 | 22 | 1048 | 0.020 | |
| R | Insular cortex | 13 | 38 | 18 | 6 | 472 | 0.014 | |
| R | Parietal lobe, inferior parietal lobule | 40 | 32 | −46 | 42 | 464 | 0.014 | |
| HR youths > BD youths (6 experiments) | R | Dorsolateral prefrontal cortex | 9 | 46 | 8 | 22 | 1056 | 0.020 |
| L | Cerebellum | −8 | −50 | −26 | 944 | 0.022 | ||
| R | Insular cortex | 13 | 38 | 18 | 6 | 496 | 0.014 | |
| BD > TD (43 experiments) | R | Amygdala, limbic lobe, parahippocampal gyrus, | 26 | −2 | −12 | 1120 | 0.0221 | |
| R | Frontal lobe, medial prefrontal cortex | 10 | 4 | 62 | 14 | 872 | 0.030 | |
| 12 | 40 | 10 | 568 | 0.023 | ||||
| L | Ventral striatum | −16 | −12 | 28 | 640 | 0.024 | ||
| R | Somatosensory association cortex | 7 | 42 | −58 | 48 | 576 | 0.020 | |
| 2 | −64 | 56 | 392 | 0.019 | ||||
| L | Cerebellum | −16 | −36 | −24 | 560 | 0.022 | ||
| L | Lentiform nucleus, putamen, lateral globus pallidus | −22 | 6 | −4 | 464 | 0.018 | ||
| −12 | 4 | −6 | 368 | 0.017 | ||||
| −16 | −4 | −8 | 0.013 | |||||
| L | Ventrolateral prefrontal cortex | 47 | −30 | 20 | −8 | 336 | 0.017 | |
| R | Subgenual cingulate cortex | 25 | 2 | 0 | −4 | 256 | 0.016 | |
| TD > PBD (21 experiments) | R | Dorsal cingulate cortex | 32 | 2 | 36 | 12 | 1576 | 0.017 |
| R | Dorsal striatum | 10 | 10 | 6 | 696 | 0.014 | ||
| R | Ventrolateral prefrontal cortex | 47 | 38 | 24 | −4 | 336 | 0.011 | |
| R | Dorsolateral prefrontal cortex | 8 | 32 | 24 | 38 | 224 | 0.013 | |
| R | Superior frontal gyrus | 10 | 24 | 48 | 2 | 216 | 0.011 | |
R: right, L: left.
Figure 2Results from pairwise activation likelihood estimation (ALE) analysis. (A) High-risk youth > typically developing youth. (B) High-risk youth > youth with bipolar disorder. (C) Youth with bipolar disorder > typically developing youth. (D) Typically developing youth > youth with bipolar disorder. (A) DLPFC: dorsolateral prefrontal cortex, x = 46, y = 8, z = 22, cluster size = 1048 mm3, extreme value = 0.020; (B) DLPFC: x = 46, y = 8, z = 22, cluster size = 1056 mm3, extreme value = 0.020; (C) Amygdala: x = 26, y = −2, z = −12, cluster size = 1120 mm3, extreme value = 0.022; (D) DLPFC: x = 32, y = 24, z = 38, cluster size = 224 mm3, extreme value = 0.013; VLPFC: ventrolateral prefrontal cortex.